يعرض 1 - 20 نتائج من 100 نتيجة بحث عن '"Forscher, Charles"', وقت الاستعلام: 0.61s تنقيح النتائج
  1. 1
    Periodical
  2. 2
    Academic Journal

    المصدر: Journal of Clinical Oncology. 40(22)

    وصف الملف: application/pdf

  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal

    المصدر: Articles publicats en revistes (Ciències Clíniques)

    مصطلحات موضوعية: Sarcoma, Placebos, Placebos (Medicine)

    وصف الملف: 15 p.; application/pdf

    Relation: Reproducció del document publicat a: https://doi.org/10.1200/JCO.21.01829; Journal of Clinical Oncology, 2022, vol. 40, num. 22, p. 2479-2490; https://doi.org/10.1200/JCO.21.01829; http://hdl.handle.net/2445/190172; 732593

  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal
  12. 12
  13. 13
  14. 14
    Academic Journal
  15. 15
  16. 16
    Academic Journal

    وصف الملف: application/pdf

    Relation: Schuetze, Scott M.; Bolejack, Vanessa; Choy, Edwin; Ganjoo, Kristen N.; Staddon, Arthur P.; Chow, Warren A.; Tawbi, Hussein A.; Samuels, Brian L.; Patel, Shreyaskumar R.; Mehren, Margaret; D’Amato, Gina; Leu, Kirsten M.; Loeb, David M.; Forscher, Charles A.; Milhem, Mohammed M.; Rushing, Daniel A.; Lucas, David R.; Chugh, Rashmi; Reinke, Denise K.; Baker, Laurence H. (2017). "Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor." Cancer 123(1): 90-97.; https://hdl.handle.net/2027.42/135187; Cancer; Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012; 23: 3171 – 3179.; Yamada Y, Kohashi K, Fushimi F, et al. Activation of the Akt‐mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors. Cancer. 2014; 120: 864 – 876.; Hindi N, Casali PG, Morosi C, et al. Imatinib in advanced chordoma: a retrospective case series analysis. Eur J Cancer. 2015; 51: 2609 – 2614.; Italiano A, Le Cesne A, Bellera C, et al. GDC‐0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute single‐arm phase II collaborative study. Ann Oncol. 2013; 24: 2922 – 2926.; Chugh R, Dunn R, Zalupski MM, et al. Phase II study of 9‐nitro‐camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005; 23: 3597 – 3604.; Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F. WHO classification of tumours of soft tissue and bone. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, eds. World Health Organization Classification of Tumours. Lyon, France: International Agency for Research on Cancer; 2013: 468.; Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753 – 1759.; Demetri GD, Lo Russo P, MacPherson IR, et al. Phase I dose‐escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009; 15: 6232 – 6240.; Schuetze SM, Wathen JK, Lucas DR, et al. SARC009: phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma. Cancer. 2016; 122: 868 – 874.; Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukemia. N Engl J Med. 2010; 362: 2260 – 2270.; van Oosterwijk JG, van Ruler MA, Briaire‐de Bruijn IH, et al. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br J Cancer. 2013; 109: 1214 – 1222.; Schrage YM, Briaire‐de Bruijn IH, de Miranda NF, et al. Kinome profiling of chondrosarcoma reveals SRC‐pathway activity and dasatinib as option for treatment. Cancer Res. 2009; 69: 6216 – 6222.; Akhavan‐Sigari R, Gaab MR, Rohde V, Abili M, Ostertag H. Expression of PDGFR‐alpha, EGFR and c‐MET in spinal chordoma: a series of 52 patients. Anticancer Res. 2014; 34: 623 – 630.; Lee DH, Zhang Y, Kassam AB, et al. Combined PDGFR and HDAC inhibition overcomes PTEN disruption in chordoma. PLoS One. 2015; 10: e0134426.; Pennacchioli E, Fiore M, Collini P, et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol. 2010; 17: 3229 – 3233.; Portera CA Jr, Ho V, Patel SR, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer. 2001; 91: 585 – 591.; Spitz FR, Bouvet M, Pisters PW, Pollock RE, Feig BW. Hemangiopericytoma: a 20‐year single‐institution experience. Ann Surg Oncol. 1998; 5: 350 – 355.; Guzzetta AA, Montgomery EA, Lyu H, et al. Epithelioid sarcoma: one institution’s experience with a rare sarcoma. J Surg Res. 2012; 177: 116 – 122.; Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011; 22: 1682 – 1690.; Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013; 31: 2296 – 2302.; Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011; 117: 4939 – 4947.; Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012; 30: 914 – 920.; Pink D, Richter S, Gerdes S, et al. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi‐institutional analysis. Oncology. 2014; 87: 95 – 103.; Jones RL, Constantinidou A, Olmos D, et al. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012; 35: 351 – 357.; Jawad MU, Extein J, Min ES, Scully SP. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res. 2009; 467: 2939 – 2948.; Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFR‐positive chordoma. Ann Oncol. 2013; 24: 1931 – 1936.

  17. 17
    Academic Journal
  18. 18
  19. 19
    Academic Journal
  20. 20
    Academic Journal